3. Study characteristics of studies with HFpEF.

Reference	Number of centres	Intervention	Ivabradine [n]	Placebo/SC [n]	Dosage	Duration IP	Timing outcomes	Ejection fraction [%]	Guideline adherence***
Short‐term treatment (< 6 months) with ivabradine
De Masi De Luca 2013*	ns	Ivabradine Placebo	53	58	5 mg/7.5 mg twice a day	ns	M 0, 3	EF ≥ 50	ns
Kosmala 2013	3	Ivabradine Placebo	30	31	5 mg twice a day	W 1	D 0, 7	LVEF ≥ 50	ns
Long‐term treatment (≥6 months) with ivabradine
Komajda 2017	86	Ivabradine Placebo	95	84	2.5 mg/5 mg/7.5 mg twice a day	M 8	M 0, 2, 4, 8	LVEF ≥ 45	BB (74.3%); ACE inhibitor or ARB (87.2%); MRA (29.3%)
			∑ 178	∑ 173

*Reported only as abstract.
**Initial dose 5 mg twice a day; after 2 weeks with a heart rate of 60/min or higher: 7.5 mg twice a day; if heart rate dropped below 50/min or other clinical symptoms of bradycardia: again 5 mg twice a day; if symptoms did not improve: ivabradine treatment stopped.
***According to the European Society of Cardiology (ESC) Clinical Practice Guideline on Acute and Chronic Heart Failure (Ponikowski 2016).

Abbreviations: ns = not specified; M = month; W = week; D = day; ACE inhibitor = angiotensin‐converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta‐blockers; EF = ejection fraction; IP = interventional prodcut; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; SC = standard care